Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,243 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chronic Obstructive Pulmonary Disease (COPD) Clear all

Conditions: COPD
Interventions: Use of Telehealth equipment (Viterian V-100); Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Omaha, Nebraska

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: PH-797804, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 22
States / cities: Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • Jasper, Alabama • Torrance, California + 8 more

Conditions: Chronic Obstructive Lung Disease
Interventions: Breathe NIOV Ventilator; Device
Lead sponsor: Breathe Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions: Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise; Drug · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions: Values Inventory (VI); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: ADAPT Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16,568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 506
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 110
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium + olodaterol, tiotropium, olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 2,624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 35
States / cities: Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: In Check Dial test; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: COPD, Heart Failure, Cancer
Interventions: Storytelling Intervention for Patient Participants, Storytelling Intervention for Nurse Participants; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled treprostinil solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 28
States / cities: Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more

Conditions: Chronic Obstructive Pulmonary Disease, Physical Activity, Health Behavior
Interventions: Telephonic health coaching; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Tucson, Arizona • Riverside, California • San Diego, California + 24 more

Conditions: Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions: LungGuard, BAROGuard; Device
Lead sponsor: Paragonix Technologies; Industry
Eligibility: Not listed
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 27
States / cities: Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more

Conditions: Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COPD
Interventions: SpiroPD; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 92
States / cities: Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more

Search by objective public record fields.

VISN 23 Chronic Obstructive Pulmonary Disease (COPD) Case Management Using Home Telehealth Equipment

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Chronic Obstructive Pulmonary Disease Endpoints Study

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

Advancing Symptom Alleviation With Palliative Treatment

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)

Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

The ROAM Research Study Therapy (LTOT) Version

Tezepelumab COPD Exacerbation Study

Vascular Subphenotypes of Lung Disease in HIV & COPD

Feasibility of At-Home Handheld Spirometry

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation